site

Monitoring Patient Glucose Levels: New Advances in software make it easier

...daily for analysis and can be sent to a secure web site online. The physician can log onto the secure web site to view a graph of daily glucose levels for patients, read a summary of relevant statistics for the ...

Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance

... or epithelial surfaces, the most common colonized site being the anterior nares. Sites of colonization are important not only as a source of subsequent infection, but also serve as a reservoir for transmission. Although frequent antibiotic use in healthcare settings selects for resistant flora, genetic...

Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing

...ty results. POCT places a burden on department and site directors to properly identify the training needs of non-laboratorians, and to ensure that they are met. Additionally, non-laboratorian staff trained on POCT methods must be monitored following the trainings in order to insure their competency with t...

Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology

...y providingeducational information through its Web site at <a target="_blank"href="http://www.aaaai.org/">http://www.aaaai.org . CONTACT: Natalie Lemke, , or Amber Johnson,, +1-414-272-6071,both of the AAAAI <a target="_blank" href="mailto:nlemke@aaaai.org">nlemke@aaaai.org <a target...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

...ated with AGGRASTATR occurs at the arterial access site forcardiac catheterization. Fatal bleedings have been reported.AGGRASTATR should be used with caution in patients with plateletcount less than 150,000/mm3, in patients with hemorrhagicretinopathy and in patients in chronic hemodialysis. BecauseAGGRAS...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

...remaining three events consisted of mild injection site erythema (redness) that occurred on the day of the co-injection and resolved within one or two days. As a spreading agent, hyaluronidase has traditionally been usedto accelerate the delivery of drugs and fluids, including localanesthetic...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

...the Anticalin(R) candidate is viamodulation of the site of binding for multiple ligands. "This important milestone demonstrates the exciting potential ofAnticalin(R)-based products for the treatment of respiratorydisease," said Dr Andreas Hohlbaum, Director of Science andPreclinical Development of Pieris...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

...mation about AVI is available on the company's Web site athttp://www.avibio.com. About Cook Medical Cook Medical was the first company to introduce interventionaldevices in the United States. Today, the company participates inall global markets, integrating device design, biopharma, gene andcell thera...

Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference

...ugh the Investor Relations section ofAccelrys' web site at www.accelrys.com or by visiting the followingweb address: http://www.wsw.com/webcast/ceut6/accl/. To learn more about C.E. Unterberg, Towbin, please visitwww.unterberg.com. About Accelrys, Inc. Accelrys develops and commercializes Scientific Bu...

Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

...the presentation will be available on Inspire'sweb site at www.inspirepharm.com. An archived version of thewebcast presentation will also be available through this link for alimited time following the conference. About Inspire Inspire is a biopharmaceutical company dedicated to discovering,developing an...

Tercica to Present at Investment Conferences

...visiting the Investors section of the Company'sWeb site at www.tercica.com. An archived presentation will beavailable on the Web site for 21 days. Tercica also announced management's participation in the PacificGrowth Equities One on...

Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference

...ks will also be available through theCompany's web site for a limited time following the conference. About Micromet, Inc. (<a target="_blank" href="http://www.micromet-inc.com/">www.micromet-inc.com ) Micromet, Inc. is a biopharmaceutical company focusing on thedevelopment of novel, proprietary ...

SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

...theInvestor Relations section of the Company's Web site at <a target="_blank" href="http://www.supergen.com/">http://www.supergen.com . The webcastwill be archived for 90 days. About SuperGen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceuticalcompany dedicated to the discovery, rapid dev...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...hnson & Johnson, please visit theCompany's web site at www.jnj.com. Contact For Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Ernie Knewitz, 908-927-2953 <a target="_blank" href="mailto:eknewitz@prdus.jnj.com">eknewitz@prdus.jnj.com or Steven Cooper, 415-486-3264 &...

Stanford Researchers Find Brain Pathway of Depression in Rats

...tanford. For moreinformation, please visit the Web site of the medical center'sOffice of Communication & Public Affairs athttp://mednews.stanford.edu. Contact Stanford University Medical Center Print Media: Mitzi Baker, 650-725-2106 <a target="_blank" href="mailto:mabaker@stanford.edu">mab...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

...Formore information on Suven, please visit our Web site at <a target="_blank" href="http://www.suven.com/">http://www.suven.com Risk Statement: Except for historical information, all of the statements,expectations and assumptions, including expectations andassumptions, contained in this news r...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

...esearch at Mayo Clinic Cancer Center,visit the Web site at <a target="_blank" href="http://cancercenter.mayo.edu/">http://cancercenter.mayo.edu .<a target="_blank" href="http://www.mayoclinic.org/news2007-rst/4117.html?src=email-release">http://www.mayoclinic.org/news2007-rst/4117.html?src...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

... showed that when it is locallyadministered to the site of pain, there appears to be limitedsystemic exposure. Its short duration of systemic exposure (hours)relative to the long duration of analgesia (12 weeks) resultingfrom a single treatment course of Adlea is particularly importantin this typically el...

Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine

..." The poster will be available on Labopharm's web site (<a target="_blank" href="http://www.labopharm.com/">www.labopharm.com ) onMonday, July 2, 2007 following conclusion of the Forum. In addition, representatives of the Company will be atLabopharm's corporate booth to promote its once-daily tr...

Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford

...tanford. For moreinformation, please visit the Web site of the medical center'sOffice of Communication & Public Affairs athttp://mednews.stanford.edu. Ranked as one of the best pediatric hospitals in the nation byU.S.News & World Report and Child magazine, Lucile PackardChildren's Hospital at Sta...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

...land. Formore information, visit the company's Web site at <a target="_blank" href="http://www.medimmune.com/">http://www.medimmune.com . About Abbott Abbott is a global, broad-based health care company devoted tothe discovery, development, manufacture and marketing ofpharmaceuticals and medical...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

...FDA. For further information,visit the Company Web site at www.biovest.com. About Accentia Biopharmaceuti...try.For further information, visit the Company Web site atwww.accentia.net. Forward-Looking Statements Statements in this release that are not strictly hi...

Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

...tollfree 800-833-3533 or by visiting Cytogen's web site atwww.cytogen.com. The Company's website is not part of this pressrelease. This press release contains certain "forward-looking" statementswithin the meaning of the Private Securities Litigation Reform Actof 1995 and Section 21E of the Securities Ex...

Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis

...try.For further information, visit the Company Web site atwww.accentia.net. Forward-Looking Statements Statements in this release that are not strictly historical innature constitute "forward-looking statements." Such statementsinclude, but are not limited to, statements about Revimmune(TM)SinuNase(TM),...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

....niddk.nih.gov/publications/health_risks.htm . Web site accessed May 2007. For further information, please contact: Media: Investors: Media: An Phan Tel (on-site): 609-558-0420 Tel (office): 609-987-4893 Christian Qvist Frandsen Tel (direct): (1) 609 919 7937 ...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

... more information, please visit Phosphagenics' web site at<a target="_blank" href="http://www.phosphagenics.com/">http://www.phosphagenics.com CONTACT: Company, Dr. Esra Ogru, Executive Vice PresidentResearch &Development, +1-646-706-2155, or Harry Rosen,President and CEO,+1-646-715-3581, bo...

HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference

...amp;Exchange Commission also maintains an Internet site that containsreports, proxy and information statements, and other informationregarding issuers that file electronically with the U.S. Securities& Exchange Commission at http://www.sec.gov. The Company makesno commitment to publicly release the re...

Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting

...ficacious in preclinical animal studies. Injection site reactionswere the most common adverse events repor... information about Sangamo, visitthe company's web site at <a target="_blank" href="http://www.sangamo.com/">http://www.sangamo.com . This press re...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

...sociated withinsulin therapy may include injection site reactions (on average3-4 percent of patients in cl...n.niddk.nih.gov/publications/health_risks.htm .Web site accessed May 2007. CONTACT: Media, An Phan, +1-609-558-0420, or +1-609-987-4893,orInvestors, Christ...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

... thereby preventing thedegradation of GLP-1 at the site of action. Unbound ARI-2243 thenundergoes a unique soft drug inactivation as it passes through thegut and into the systemic circulation, which limits the exposure ofthe active species to unwanted targets, such as DPP 8 and 9. Theconversion product, A...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

... as a deep intra-muscularinjection, with injection site pain and potential irritation andinfection. CRINONE 8% bioadhesive vaginal gel is self-administeredat home once a day using a convenient, patient-friendly, pre-filledapplicator." The full in-press article is available for purchase athttp://www.ferts...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

...armaceuticals may be obtained through Bentley'sweb site at www.bentleypharm.com. Safe Harbor Statement under the Private Securities LitigationReform Act of 1995: This press release contains forward lookingstatements, including without limitation, statements regardingBentley's Nasulin intranasal insulin p...

VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions

...trials andproducts, please visit the company's web site at www.vivus.com. Certain statements in this press release are forward-lookingwithin the meaning of the Private Securities Litigation Reform Actof 1995. These statements may be identified by the use offorward-looking words such as "anticipate," "bel...

Researchers Discover Gene For Rare Skin Disorder

...ion. For moreinformation, visit the Institutes Web site at <a target="_blank"href="http://www.nichd.nih.gov/">http://www.nichd.nih.gov . The National Institutes of Health (NIH) — The Nation'sMedical Research Agency — includes 27 Institutes andCenters and is a component of the U.S. D...

AMIA Announces 2008 Summit on Translational Bioinformatics

...ional bioinformatics activities,visit the AMIA web site at: <a target="_blank" href="http://www.amia.org/">http://www.amia.org . Contact: Tia Abner 301-657-1291 ext. 105 tia@amia.org About AMIA The American Medical Informatics Association (AMIA) is aprofessional...

MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions

...ges while takingACTOS. Please visit the ACTOS Web site at <a target="_blank" href="http://www.actos.com/">www.actos.com for Complete PrescribingInformation. Takeda Pharmaceuticals North America, Inc. Based in Deerfield, Ill., Takeda Pharmaceuticals North America,Inc., is a wholly owned subsidi...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

...r core scaffold provides a highlyselective binding site with high structural plasticity and anextensive binding surface comparable to that achieved withantibodies. The adaptability of the Anticalin(R) scaffold hasalready allowed Pieris to develop therapeutic and diagnosticproduct candidates with custom de...

Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis

...T-cells. The safety profilerevealed only injection site mild reactions and no severe adversereactions related to T-cell vaccination. Both Phase I/II clinical studies have demonstrated that T-cellvaccination depletes myelin reactive T-cells in peripheral blood.In the extension study patient population, t...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

... access thelive webcast, please log on to Amylin's site approximately 15minutes prior to the presentation to register and download anynecessary audio software. More information about ADA can be found at<a target="_blank" href="http://scientificsessions.diabetes.org/">http://scientificsessions...

Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial

...rnet fromthe investor section of the company's Web site or by dialing thenumbers listed below. A detailed PowerPoint presentation willaccompany the webcast. Conference Call Details: Dial-In: (800) 291-5365 (U.S.) (617) 614-3922 (International) ...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

...ined in the plasma and in the liver, the principal site of HCVreplication. "The current standard of care is inadequate for many chronic HCVpatients, including about half of those with genotype 1 disease,"said Steve Worland, Ph.D., president, Pharmaceuticals. "We believeANA598 possesses favorable characte...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

...nt may vary based on a number of factors,including site initiation and patient enrollment rates. About Pe...nd theinvestors/media section of the Company's web site at <a target="_blank" href="http://www.allos.com/">http://www.allos.com andwill be archived...

Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data

...tration (badtaste, throat irritation, instillation site reaction, nasalerythema, nasal irritation) were more common with Rylomine orintranasal placebo than the intravenous morphine groups. Generalsystemic adverse events related to active drug were similar acrossmorphine treatment groups regardless of rout...

Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study

...ontact the Company at 919-862-1000or visit our web site at www.salix.com. Information on our web siteis not incorporated in our SEC filings. Please Note: This press release contains forward-lookingstatements regarding future events. These statements are justpredictions and are subject to risks and uncert...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

...ther information are available onthe company's Web site at <a target="_blank" href="http://www.abbott.com/">http://www.abbott.com . CONTACT: International Media, Kellie Harris, +1-847-937-9789, orU.S.Media, Elizabeth Shea, +1-847-935-2211, or Financial, JohnThomas,+1-847-938-2655, all of Abbott ...

Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey

... are dry mouth, dysphagia, dyspepsia, andinjection site pain. These adverse events are generally mild tomoderate, transient, self-resolving, and more common with higherdoses. MYOBLOC is supplied as a ready-to-use, injectable solutionin three single-dose vial sizes of 0.5 mL (2500 U), 1.0 mL (5000U), and 2...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

...e company is based in Kenilworth, N.J., and itsWeb site is <a target="_blank" href="http://www.schering-plough.com/">www.schering-plough.com . SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this pressrelease contains certain "forward-looking" statements within themeaning of the Private Sec...

Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study

...e company is based in Kenilworth, N.J.,and its Web site is <a target="_blank" href="http://www.schering-plough.com/">www.schering-plough.com SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this pressrelease contains certain "forward-looking" statements within themeaning of the Private Secu...

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

...f lymphoma is unknown-- ENBREL can cause injection site reaction-- In a medical study of patients with JRA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults -- The kinds of infections reported were generally mild and similar to those usually se...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

...hat is intended for transplantationinto the lesion site of patients with spinal cord injury to inducetissue repair. Geron's development plan for the product calls forthe filing of an Investigational New Drug (IND) Application withthe U.S. Food and Drug Administration later this year pending theoutcome of ...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

...lopment programs, visit the Company's Internet web site at<a target="_blank" href="http://www.vionpharm.com/">www.vionpharm.com . This news release contains forward-looking statements. Suchstatements are subject to certain risk factors which may causeVion's plans to differ or results to vary from...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

...lease visit theEuropean Hematology Association Web site at <a target="_blank"href="http://congress.ehaweb.org/12th">http://congress.ehaweb.org/12th . About PNH PNH is an acquired genetic blood disorder defined by hemolysis,in which patients' red blood cells are destroyed by complement, acomponen...

IMPAX Presents at Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders

...the Investor Relations sectionof the Company's Web site by clicking on Presentations. Comparison of Pharmacokinetics and Pharmacodynamics of CombinedImmediate- and Extended-Release (IR+ER) Carbidopa/LevodopaFormulations (VADOVA IR+ER) with IR Carbidopa/Levidopa andControlled-Release Carbidopa/Levodopa in ...

Prana Biotechnology Presents New Key Findings on PBT2

...gy. For further information, please visit our web site at <a target="_blank" href="http://www.pranabio.com/">www.pranabio.com <<a target="_blank" href="http://www.pranabio.com/">http://www.pranabio.com/ > . Forward Looking Statements This press release contains "forward-looking ...

Dynogen Reports Positive Results in Phase 1B GERD Study

...ct candidate remains availableat the desired local site of action. A recently completed Phase 2study of the candidate as a treatment for IBS-c demonstrated anoverall clinical response rate of 54% in patients receiving a doseof 1.4 mg t.i.d. compared to a 15% clinical response rate forpatients receiving pl...

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

...an toll-free number 1 877680-4500 or visit our Web site at <a target="_blank" href="http://www.neurochem.com/">www.neurochem.com . (1) Cochran-Mantel-Haenszel row mean-scores test (2) Cox proportional-hazards analysis. This news release contains forward-looking statements regardingeprodisate (K...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

...t site, withthe most frequent being mild injection site pain. Objective tumor responses, defined as 50% t...howed activity in untreated tumors distantfrom the site of administration of the therapy, including onesubject showing shrinkage and disappearance of lung t...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

...rugs can be givensafely to patients, can reach the site of action in cancer cellsand are potent enough to induce clinically relevant benefits, evenwhen given for only a brief period. This is encouraging for therapidly advancing new field of RNA targeted medicines and for thefuture of RNA Antagonists in pa...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

...ks after therapy. Results from the Goshen study site were reported at the meeting.Eleven patients, of w...MUC1 antigen targeted by PAM4, and asingle binding site for the histamine-succinyl-glycine (HSG)peptide. Initial therapy studies showed that pretargeting wi...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

...tthe U.S. Securities and Exchange Commission's web site at<a target="_blank" href="http://www.sec.gov/">http://www.sec.gov , at AstraZeneca'swebsite at <a target="_blank" href="http://www.astrazeneca.com/">http://www.astrazeneca.com or atMedImmune's website at <a target="_blank" href=...